Wolgang Hiddemann, MD, PhD, received his medical degree from the Rheinische Friedrich-Wilhelms-Universitat in Bonn, Germany and the Westfälische Wilhelms-Universität in Münster, Germany, in 1974. He then worked as a doctoral assistant at Münster University Hospital where he specialized in internal medicine. Prof. Hiddemann also undertook a research stay at Memorial Sloan-Kettering Cancer Center in New York City, NY, from 1978-1979.
In 1986, Prof. Hiddemann became a senior physician, specializing in hematology and oncology soon afterwards. In 1992, he was appointed Director of the Department for Hematology and Oncology at the Georg-August University in Göttingen, Germany, after which he served as Director of the Medical Clinic II at the Ludwig Maximilians University Hospital in Munich, Germany, until 2017.
On his initiative, the non-profit organization “Lebensmut – Life with Cancer eV” was founded in 1999, which is dedicated to the promotion of the psycho-oncological care of patients and their relatives.
Prof. Hiddemann is a member of the editorial board of several journals including the Annals of Oncology, Der Internist, the Germany Medical Weekly and Leukemia. He is also a member of various specialist societies such as the German Society for Hematology and Medical Oncology and the German Cancer Aid Foundation.
Speaking on novel therapies for AML and lymphomas
Prof. Hiddemann’s research is primarily concerned with the pathogenesis and treatment of acute leukemias, including acute myeloid leukemia (AML), and low-grade lymphomas. He is the lead on several multicenter clinical trials, including many which are investigating monoclonal antibody therapies for AML.